Company news

Paradigm Biopharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

iPPS Phase 2 Biomarker Results Published in Leading Journal

January 28, 2026

Phase 3 Knee OA Trial Recruitment Update

December 22, 2025

Drawdown of Tranche 2 under the Convertible Note Facility

November 17, 2025

September 2025 Quarterly Activities Report & Appendix 4C

October 29, 2025

Phase 3 Knee OA Trial Recruiting and Dosing in AUS & US

September 30, 2025

Appendix 4E and 2025 Annual Report

August 29, 2025

June 2025 Quarterly Activities Report & Appendix 4C

July 28, 2025

Paradigm Secures US$27M to Advance Phase 3 OA Trial

June 30, 2025

Paradigm Strengthens OA Pipeline with Strategic Acquisition

June 25, 2025

PAR Receives US Ethics Approval for Phase 3

May 14, 2025

March 2025 Quarterly Activities Report & Appendix 4C

April 29, 2025

S&P DJI Announces March 2025 Quarterly Rebalance

March 7, 2025

Paradigm Secures Ethics Approval for Phase 3 Trial

February 23, 2025

Loyalty and Piggyback Options Program

January 31, 2025

PAR Selects Advanced Clinical as CRO for Phase 3

January 30, 2025

Quarterly Activities/Appendix 4C Cash Flow Report

January 30, 2025

Paradigm Receives $6.3m R&D Tax Refund

January 23, 2025

PAR Capital Raising Presentation

December 8, 2024

Successful Completion of $16M Placement for Phase 3

December 8, 2024

Trading Halt

December 4, 2024

Paradigm to Proceed with Phase 3 Knee OA Trial

November 27, 2024

Response to ASX Price Query

November 25, 2024

2024 Chairman Address and AGM Presentation

November 18, 2024

Phase 3 Protocol Submission to US FDA

October 30, 2024

Paradigm Investor Update

October 20, 2024

PAR receives positive response from US FDA for phase 3

September 17, 2024

Appendix 4E and 2024 Annual Report

August 30, 2024

Type D Response Submitted and Received by the US FDA

April 18, 2024

Half Yearly Report and Accounts

February 28, 2024

Primary Endpoint Achieved in Phase 2 MPS VI Trial

February 8, 2024

Paradigm Receives $7.36m R&D Tax Incentive Refund

February 6, 2024

Security Class Reinstatement to Quotation PARO

November 27, 2023

Successful completion of Retail Entitlement Offer

November 23, 2023

Security Class Suspension from Quotation PARO

November 20, 2023

Paradigm to Recommence Trading

October 31, 2023

Replacement Entitlement Offer and Placement Prospectus

October 31, 2023

PAR Successful Placement and Fully Underwritten ANREO

October 31, 2023

Entitlement Offer and Placement Prospectus

October 29, 2023

Investor Presentation - $30m Capital Raise

October 29, 2023

Paradigm Launches $30M Capital Raising

October 29, 2023

iPPS Increases Cartilage Thickness in Phase 2 Trial

October 17, 2023

Ipps significant oa pain reduction at 12 months

October 9, 2023

2023 Annual Report and Appendix 4E

August 25, 2023

PAR Reports Phase 3 Clinical Trial Update

July 3, 2023

Primary and Secondary endpoints met in MPS I Trial

June 6, 2023

iPPS shows 3-year equivalent durability in OA Canine Study

May 31, 2023

iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study

April 3, 2023

Phase 3 OA Trial to Proceed after Formal Safety Review

December 28, 2022

PAR Receives Allowance for Key US Patent

December 11, 2022

Paradigm CEO steps down & Appointment of MD

November 21, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 30 decks. Every deck is listed under its year.